Inhaled salbutamol and doping control: effects of dose on urine concentrations

Sporer, B.C.; Sheel, A.W.; Taunton, J.; Rupert, J.L.; McKenzie, D.C.

Clinical Journal of Sport Medicine Official Journal of the Canadian Academy of Sport Medicine 18(3): 282-285


ISSN/ISBN: 1050-642X
PMID: 18469572
DOI: 10.1097/jsm.0b013e3181705c8c
Accession: 053861817

Download citation:  

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

The present study was designed to examine the dose-response relationship of inhaled salbutamol and its concentration in the urine while resting at various times after inhalation, and to compare these values against the current World Anti-Doping Code limits. An interventional, repeated-measures design. Sport Medicine Clinic, University of British Columbia (Vancouver, Canada). Eight healthy, nonasthmatic males participated in this study (age = 28 +/- 6 years, height = 179.4 +/- 5.1 cm, and weight = 77.4 +/- 5.4 kg). Administration of three different doses of inhaled salbutamol (800, 400, and 200 microg) in a randomized fashion separated by at least 72 hours. Urine concentration of nonsulphated salbutamol Urine concentrations were highly variable between subjects and increased as dose increased, with a significant difference noted between 800 and 200 microg at 30, 60, and 120 minutes after inhalation. Urine concentrations of salbutamol peaked at 60 minutes for all doses. No samples exceeded the doping criterion of 1000 ng/mL, and the maximum value observed was 904 ng/mL. These results indicate that after inhalation of doses up to 800 microg, urinary concentrations of salbutamol are well below the limits used in doping control.